Atea Pharmaceuticals is an American clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. The company was incorporated in 2012 and is based in Boston, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Atea Pharmaceuticals news
10.05.2022
Atea Pharmaceuticals' GAAP loss for 3 months of 2022 was $42.077 million, compared to a profit of $30.713 million in the previous year. The company did not receive any revenues. A year earlier the figure was $65.985 million.
Source: 
ir.ateapharma.com
ir.ateapharma.com
01.03.2022
Net profit of Atea Pharmaceuticals under GAAP for 2021 amounted to $121.19 million, against a loss of $10.947 million in the previous year. Revenue increased 7.2 times to $351.367 million from $48.633 million a year earlier.
Source: ir.ateapharma.com
ir.ateapharma.com
12.11.2021
Atea Pharmaceuticals reported a GAAP net profit of $4.058 million for 9M 2021, compared to a loss of $31.603 million in the previous year. The revenues amounted to $159.187 mln. In the same period of the previous year the company had no revenues.
Source: ir.ateapharma.com
ir.ateapharma.com
13.08.2021
Atea Pharmaceuticals' GAAP net income for 6M 2021 was $32.252 million, compared to a loss of $13.981 million in the previous year. The company generated $126.376 million in revenues.
Source: ir.ateapharma.com
ir.ateapharma.com
General information
| Company name | Atea Pharmaceuticals |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 125 Summer Street Boston, MA 02110 United States |
| Mailing address | 125 Summer Street Boston, MA 02110 United States |
| Website | ir.ateapharma.com |
| Information disclosure | www.sec.gov |
English (US) 